Acquisition costs and yen bite into Eisai's profits
This article was originally published in Scrip
Eisai expects its net profit to fall by 5% to ¥67.0 billion ($747.8 million) this fiscal year. Profits have been hit by a combination of the strong yen, investment losses and amortisation costs related to its acquisition of MGI Pharma.
You may also be interested in...
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.